Myocardial Ketones Metabolism in Heart Failure.

Ketone energy metabolism heart failure ketogenic diet metabolic remodeling sodium-glucose cotransporter-2 inhibitors

Journal

Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 10 01 2020
revised: 18 03 2020
accepted: 09 04 2020
pubmed: 23 5 2020
medline: 19 8 2021
entrez: 23 5 2020
Statut: ppublish

Résumé

Ketone bodies can become a major source of adenosine triphosphate production during stress to maintain bioenergetic homeostasis in the brain, heart, and skeletal muscles. In the normal heart, ketone bodies contribute from 10% to 15% of the cardiac adenosine triphosphate production, although their contribution during pathologic stress is still not well-characterized and currently represents an exciting area of cardiovascular research. This review focuses on the mechanisms that regulate circulating ketone levels under physiologic and pathologic conditions and how this impacts cardiac ketone metabolism. We also review the current understanding of the role of augmented ketone metabolism as an adaptive response in different types and stages of heart failure. This analysis includes the emerging experimental and clinical evidence of the potential favorable effects of boosting ketone metabolism in the failing heart and the possible mechanisms of action through which these interventions may mediate their cardioprotective effects. We also critically appraise the emerging data from animal and human studies which characterize the role of ketones in mediating the cardioprotection established by the new class of antidiabetic drugs, namely sodium-glucose co-transporter inhibitors.

Identifiants

pubmed: 32442517
pii: S1071-9164(20)30033-6
doi: 10.1016/j.cardfail.2020.04.005
pii:
doi:

Substances chimiques

Ketone Bodies 0
Ketones 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

998-1005

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Qutuba G Karwi (QG)

Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada; Department of Pharmacology, College of Medicine, University of Diyala, Diyala, Iraq. Electronic address: karwi@ualberta.ca.

Dipsikha Biswas (D)

Department of Biochemistry and Molecular Biology, Dalhousie Medicine New Brunswick, Dalhousie University, Saint John, New Brunswick, Canada. Electronic address: dp369152@dal.ca.

Thomas Pulinilkunnil (T)

Department of Biochemistry and Molecular Biology, Dalhousie Medicine New Brunswick, Dalhousie University, Saint John, New Brunswick, Canada.

Gary D Lopaschuk (GD)

Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH